Denier C, Ducot B, Husson H, Lozeron P, Adams D, Meyer L, Said G, Planté-Bordeneuve V
Dept. of Neurology, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin Bicêtre, France.
J Neurol. 2007 Dec;254(12):1684-8. doi: 10.1007/s00415-007-0617-5. Epub 2007 Dec 14.
Familial amyloid polyneuropathies (FAP) patients manifest progressive sensory-motor length dependent polyneuropathy and severe autonomic dysfunction. In this setting the autonomic manifestations include mainly postural hypotension, nausea and vomiting, diarrhea and constipation, sphincter distur- bances and erectile dysfunction. Reproducible quantitative evaluation of signs and symptoms are necessary for the assessment of treatment efficacy.
To determine the reliability of a new compound test cumulating evaluation of autonomic and sensorymotor dysfunction in FAP.
Compound Autonomic Dysfunction Test (CADT) is a new questionnaire to evaluate the main symptoms of autonomic dysfunction observed in FAP. A separate functional questionnaire assesses the disability due to the sensorymotor deficit (Modified Norris Test; MNT). The compound test takes approximately 10 minutes to perform. In this prospective study, we enrolled consecutively 60 FAP patients to test interexaminer reliability, i.e., both questionnaires rated independently by 2 examiners. We also evaluate the reliability of testing patients face to face and by phone call, by the same examiner.
Interexaminer reliabilities tested were high (ICC=0.92 for the CADT, p < 0.001; and ICC = 0.99 for the MNT, p < 0.001). In addition, testing by phone as compared to testing during the initial medical visit by the same investigator gave similar results (ICC = 0.91 for the CADT, p < 0.001; and ICC = 0.98 for the MNT, p < 0.001).
In FAP, the CADT and the MNT have good reliability inter-investigators as well as between face to face and by phone call, by the same examiner. This newly designed compound test is a simple and reproducible scale which is adapted to evaluate the main neuropathic manifestations and will be useful for assessment of future treatments in this condition.
家族性淀粉样多神经病(FAP)患者表现为进行性感觉运动性长度依赖性多发性神经病和严重的自主神经功能障碍。在这种情况下,自主神经表现主要包括体位性低血压、恶心和呕吐、腹泻和便秘、括约肌功能障碍以及勃起功能障碍。对体征和症状进行可重复的定量评估对于评估治疗效果是必要的。
确定一种累积评估FAP自主神经和感觉运动功能障碍的新复合测试的可靠性。
复合自主神经功能障碍测试(CADT)是一种新的问卷,用于评估FAP中观察到的自主神经功能障碍的主要症状。另一份功能问卷评估感觉运动缺陷导致的残疾情况(改良诺里斯测试;MNT)。进行该复合测试大约需要10分钟。在这项前瞻性研究中,我们连续招募了60名FAP患者,以测试检查者间的可靠性,即两份问卷由两名检查者独立评分。我们还评估了由同一名检查者面对面和通过电话对患者进行测试的可靠性。
测试的检查者间可靠性较高(CADT的组内相关系数ICC = 0.92,p < 0.001;MNT的ICC = 0.99,p < 0.001)。此外,与同一名研究者在初次就诊时进行测试相比,通过电话测试得到了相似的结果(CADT的ICC = 0.91,p < 0.001;MNT的ICC = 0.98,p < 0.001)。
在FAP中,CADT和MNT在不同研究者之间以及同一名检查者面对面和通过电话测试时都具有良好的可靠性。这种新设计的复合测试是一种简单且可重复的量表,适用于评估主要的神经病变表现,将有助于评估这种疾病未来的治疗效果。